🇺🇸 ImmunityBio, Inc.IBRX
Get ImmunityBio, Inc. filings on Telegram the moment they are published.
Follow ImmunityBio, Inc. on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 8-K Items 7.01, 9.01
Overview: FDA expanded the approved indication for ANKTIVA plus BCG to include patients with BCG-unresponsive NMIBC with papillary-only tumors.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest